Phase 3 N=971 Impact of Emergency Department Probiotic (LGG) Treatment of Pediatric Gastroenteritis
Gastroenteritis
Primary: Number of Participants With Modified Vesikari Scale Score >=9 — 55; 60 Participants — p=0.83
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=88 Efficacy of Lactobacillus GG With Diosmectite in Treatment Children With Acute Gastroenteritis
Diarrhea
Primary: Duration of Diarrhea — 2; 2 days — p=0.43
Phase 1 N=27 CampETEC Hyperimmune Bovine Colostrum (HBC)
Healthy Volunteer
Primary: Incidence of Adverse Events — 1; 1; 0; 1 events
N/A N=4,561 Chronic Gastrointestinal Sequelae of an Acute Outbreak of Bacterial Gastroenteritis in Walkerton Ontario
Irritable Bowel Syndrome
Primary: Number of Participants With Post Infectious Irritable Bowel Syndrome — 23; 114 participants
Phase 3 N=321 BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis
Gastroenteritis · Gastritis
Primary: Treatment Success From 30 Minutes Through 24 Hours After First Dose of Study Medication - ITT Population — 126; 70; 12; 5 Participants — p=0.0406
N/A N=1,545 Implementation of a Molecular Diagnostic for Pediatric Acute Gastroenteritis: The FilmArray GI Panel IMPACT Study
Infectious Gastroenteritis
Primary: Analysis of Diarrheal Illness Etiologies Identified in Stool Culture Compared to the FilmArray™ Gastrointestinal (GI) Panel — 434; 19 Participants
Phase 2 N=132 Norovirus Bivalent-Vaccine Efficacy Study
Prevention From Norovirus Infection
Primary: Percentage of Participants With Viral AGE Clinical Illness and Fecal Virus Excretion Detected by RT-PCR OR 4-Fold Rise In Anti-GII.4 Norovirus P Particle Antibody Titer…
N/A N=18 Effect of Elemental Diet on Adult Patients With Eosinophilic Gastroenteritis
Eosinophilic Gastroenteritis
Primary: Percent of Participants in Complete Histologic Remission — 100 percentage of participants
Phase 2 N=135 A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers
Norovirus Infections
Primary: Number of Participants With Solicited Symptoms of Reactogenicity (Gastrointestinal [GI] and Systemic) — 20; 20; 2; 9 Participants
Phase 2 N=83 IV Glucose for Dehydration Treatment
Dehydration
Primary: Measurement of Serum Ketones Before and After Administration of Intravenous Fluids for Acute Gastroenteritis — 1.10; 2.39 mmol/L — p=0.0003
Phase 2 N=4,748 Efficacy and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Adults
Healthy Volunteers
Primary: Number of Participants With Moderate or Severe Acute Gastroenteritis (AGE) Occurring for >7 Days After Dosing Due to GI.1 or GII.4 Norovirus Strains (Excluding…
N/A N=88 Gastrointestinal Myoelectric Activity Protocol, the G-Tech EEnG Protocol
Gastrointestinal Diseases
Primary: Device Success Defined as the Ability to Record Myoelectric Signals in Study Subjects. — 88 participants
N/A N=45 Clinical Experiment of Helicobacter Pylori Transmission
Infection · Achlorhydria
Primary: Development of Diarrhea — 5; 6 participants
Phase 2 N=165 Norovirus Challenge Study
Norovirus Infections
Primary: Number of Participants Who Experienced Norovirus Gastroenteritis (NVG) — 34; 37 Participants
N/A N=54 Gulf War Digestive Health Study
Irritable Bowel Syndrome · Small Intestinal Bacterial Overgrowth
Primary: Global Improvement Scale — 4.3; 4.3 units on a scale — p=0.26
Phase 4 N=147 Efficacy and Safety of a New Oral Rehydration Solution (Hipp ORS 200 Apple) in Children With Acute Gastroenteritis
Diarrhea
Primary: Number of Participants That Were Successfully Rehydrated — 57; 49 Participants — p=0.28
Phase 1 N=60 Efficacy of B7A BSIgG Against E. Coli Strain B7A Challenge
Healthy Volunteer
Primary: Safety of Serum Derived Bovine Immunoglobulins (BSIgG) — 1; 2; 0; 2 Participants
N/A N=39 Single-use Versus Multiple-use Endoscopes in Gastroenterology
Endoscopy, Gastrointestinal
Primary: Qualitative Interview Study — 18; 21 Participants
N/A N=1,555 Rotavirus Burden and Genotypes in a Sentinel Hospital Surveillance System in Lebanon
Gastroenteritis · Dehydration
Primary: Estimating the Incidence of Rotavirus Gastroenteritis Associated Hospitalization in Children < 5 Years of Age — 428 Participants
N/A N=26 Gastrointestinal Symptoms in Postural Orthostatic Tachycardia Syndrome
Postural Tachycardia Syndrome
Primary: C-peptide Levels After Oral Glucose Tolerance Test — 40.6; 23.2 pg/mL
Phase 4 N=96 Impact of Oral Application of Gastrografin on the Meconium Evacuation in Very Low Birth Weight Infants
Meconium Ileus · Very Low Birth Weight Infant
Primary: Time to Complete Meconium Evacuation in Days — 7; 8 days of life — p=0.61
N/A N=22 Aging and Gastrointestinal Barrier Function
Aging · Hyperthermia
Primary: Log Lactulose/Rhamnose Following Control Trial — 0.97; 0.79 Ratio
Phase 4 N=259 Clinical Trial of Efficacy and Safety of Ergoferon in the Treatment of Viral Intestinal Infections in Children
Viral Intestinal Infection
Primary: Average Diarrhea Duration. — 43.4; 54.7 hours — p=0.004
N/A N=24 Probiotics in Infants With Gastroschisis
Gastroschisis
Primary: Composition of the Fecal Microbiota — 42; 12; 1.1; 14 percentage of total bacteria — p=<0.01
N/A N=60 Improvements Through the Use of a Rapid Multiplex PCR Enteric Pathogen Detection Kit in Children With Hematochezia
Diarrhea Bloody
Primary: Blood Test Performance — 18; 17 Participants
N/A N=402 Multicenter Study of Patient-reported Gastrointestinal Symptoms in People With Cystic Fibrosis
Cystic Fibrosis
Primary: Number of Participants Who Fully Completed at Least One ePRO — 133; 196; 130; 194 Participants
Phase 2 N=43 A Clinical Trial to Assess Three Different Doses of OPS-2071 in Patients With Bacterial Enteritis
Bacterial Enteritis
Primary: Bacterial Elimination Rate (BER) in the CDI and EI Groups — 100.0; 72.7; 90.0; 87.5 percentage of participants
N/A N=147 Trial of Rifaximin in the Treatment of Tropical Enteropathy
Tropical Enteropathy
Primary: Difference in the Urinary L:M Ratio Before and After the Intervention — -0.01; 0.02 Ratio of lactulose-to-mannitol (L:M) exc
N/A N=99 Fear, Gastrointestinal Distress, and Interoception: Physiological and Psychological Mechanisms in Eating Disorders
Feeding and Eating Disorders
Primary: Subjective Rating of Fear — -36.9444; -23.9219; -47.3611; 85.6250 units on scale*minutes — p=.879